Amalgamated Bank Reduces Stock Holdings in United Therapeutics Corporation $UTHR

Amalgamated Bank lowered its position in United Therapeutics Corporation (NASDAQ:UTHR) by 2.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,722 shares of the biotechnology company’s stock after selling 538 shares during the quarter. Amalgamated Bank’s holdings in United Therapeutics were worth $5,954,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics in the second quarter valued at $29,000. SVB Wealth LLC purchased a new position in shares of United Therapeutics in the first quarter valued at $32,000. Geneos Wealth Management Inc. increased its position in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Brooklyn Investment Group increased its position in United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 98 shares in the last quarter. Finally, WPG Advisers LLC purchased a new stake in United Therapeutics during the 1st quarter worth about $60,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 1.8%

Shares of NASDAQ:UTHR opened at $445.43 on Friday. The stock’s 50-day moving average price is $410.07 and its two-hundred day moving average price is $337.98. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $479.50. The firm has a market cap of $20.09 billion, a price-to-earnings ratio of 16.88, a PEG ratio of 4.96 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same period last year, the company earned $6.39 EPS. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 4,000 shares of the business’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $448.96, for a total transaction of $1,795,840.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at approximately $58,364.80. The trade was a 96.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $417.50, for a total value of $9,393,750.00. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 368,435 shares of company stock valued at $152,863,012. Insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on UTHR shares. Royal Bank Of Canada lifted their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. HC Wainwright lifted their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of United Therapeutics in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $501.90.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.